Druggability & Clinical Context
Druggability
Low
Score: 0.41
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
5
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Druggability Rationale: P2Y1 exhibits high druggability (0.80 score) as a validated GPCR target with well-characterized orthosteric binding pockets demonstrated across 5 PDB structures at 2.2 Å resolution, established chemical matter (MRS2500), and precedent for purinergic receptor modulation. The availability of cryo-EM structures and AlphaFold models further supports rational drug design approaches for both antagonists and agonists.
Mechanism: GPCR antagonists or agonists modulating purinergic signaling
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:MRS2500 (investigational) — research tool
Structural Data:PDB (5) ✓AlphaFold ✓Cryo-EM ✓
Selectivity & Safety Considerations
P2Y1 selectivity faces challenges due to structural homology with other adenine nucleotide-binding P2Y receptors (P2Y12, P2Y13), requiring ligand optimization to minimize off-target platelet effects while achieving CNS penetration for neuroprotection. Selectivity advantages exist through orthosteric pocket residue differences compared to P2Y12, enabling isoform-selective antagonists.